ClinicalTrials.gg
TerminatedNCT02363946Updated Jan 12, 2026Results posted

A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)

A Phase 1 interventional study of ARC-AAT Injection and Placebo in Alpha-1 Antitrypsin Deficiency, sponsored by Arrowhead Pharmaceuticals. Terminated at 4 sites in 4 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Arrowhead Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Company decision to terminate the trial

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia — 7 open to participants now, 8 under way, 2 of them phase 3. alpha 1-Antitrypsin Deficiency · Australia.

Enrollment
11th of 18
65 · median 70
Started
2015
the only one that year
Phase 1
3 of 18
1 open now
Registered
6th of 18
by date
Lead sponsor
1 of 18
Arrowhead Pharmaceuticals

Among the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia, this one is the 11th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1, and was the 6th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

7 of the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia, or all of them as a file.
02

Study summary

The purpose of the study is to determine the safety and tolerability of escalating doses of ARC-AAT and to evaluate the pharmacokinetics of ARC-AAT and the effect of ARC-AAT on circulating levels of alpha-1 antitrypsin (AAT). The study will consist of two parts, Part A (conducted in healthy volunteers) and Part B (conducted in AATD patients) at up to 9 escalating dose levels with 6 participants per dose level.

Read the detailed description

Healthy volunteers and AATD patients will be randomized to receive a single intravenous injection of either ARC-AAT or Placebo in double-blind fashion. Up to thirteen cohorts (6 participants per cohort) will be enrolled. Participants in all cohorts will be confined to the clinical facility beginning on Day -1 with discharge on Day 2. Escalation to the next dose level will proceed until a participant experiences a dose-limiting toxicity (DLT) or there is achievement of pre-determined threshold reductions in AAT levels. Dosing in participants with AATD will commence based on pre-determined threshold reductions in AAT levels for healthy volunteers. For each participant, the duration of the study clinic visits is up to 11 weeks, from Screening to the End-of-Study examination. However, including a Day 90 Follow-Up telephone call, the maximum study duration is approximately 20 weeks.

03

Conditions studied

  • Alpha-1 Antitrypsin Deficiency

Keywords

  • alpha-1 antitrypsin
  • AATD
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(Part A - Healthy Volunteers)

  • Male or female healthy volunteers 18-50 years of age
  • Written
  • between 18.0 and 28.0 kg/m2
  • 12-lead (ECG) at Screening and pre-dose assessment with no abnormalities
  • Non-pregnant/non-nursing females
  • Non-smoker for at least one year with current non-smoking status confirmed by urine cotinine
  • Normal lung function (or not clinically significant per investigator assessment) based on spirometry and diffusion capacity of lung for carbon monoxide (DLCO) according to American Thoracic Society (ATS) - European Respiratory Society (ERS) criteria
  • Highly effective, double barrier (both male and female partners) during the study and for 3 months following the dose of ARC-AAT
  • Willing and able to comply with all study assessments and adhere to protocol schedule
  • Suitable venous access for blood sampling
  • No abnormal finding of clinical relevance at screening
  • Normal AAT level

(Part B-Patients) - As for Part A with the following exceptions:

  • Male or female patients 18-70 years of age
  • Confirmed diagnosis of homozygous alpha 1-protease inhibitor deficiency (PiZZ genotype) not receiving alpha-1 antitrypsin augmentation therapy for more than 4 weeks
  • BMI between 18.0 and 35.0 kg/m2
  • Non-smoker for at least three years with current non-smoking status confirmed by urine cotinine

Exclusion criteria

Exclusion Criteria:

(Part A-Healthy Volunteers)

  • Current regular smoker of cigarettes or cigars or was a regular smoker over the past 1 year
  • Recent (within last 6 weeks) transfusion of fresh frozen plasma, , or packed red blood cells, or anticipated need for transfusion during study
  • Acute signs of hepatitis/other infection within 4 weeks of screening and/or baseline
  • Concurrent anticoagulants
  • Use of dietary and/or herbal supplements that can interfere with liver metabolism within 7 days of screening
  • Use of any drugs known to induce or inhibit hepatic drug metabolism within 14 days prior to study treatment
  • Depot injection/implant of any drug other than within 3 months prior to study treatment
  • Diagnosis of diabetes mellitus or history of glucose intolerance
  • History of poorly controlled disease or any history of autoimmune hepatitis
  • (HIV) infection
  • Seropositive for virus (HBV) or virus (HCV), and/or history of delta virus hepatitis
  • Uncontrolled hypertension (blood pressure > 150/100 mmHg)
  • History of cardiac rhythm disturbances
  • Family history of congenital long syndrome or unexplained sudden cardiac death
  • Symptomatic heart failure (per [NYHA] guidelines)
  • Unstable angina, myocardial infarction, severe cardiovascular disease, (TIA) or cerebrovascular accident (CVA) within past 6 months
  • History of within last 5 years except adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer.
  • History of major surgery within 3 months of screening
  • Regular use of alcohol within 1 month prior to screening (i.e., more than fourteen units of alcohol per week)
  • Evidence of acute inflammation, sepsis or hemolysis or clinical evidence of lower respiratory tract infection
  • Diagnosis of significant psychiatric disorder
  • Use of illicit drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to screening or positive urine drug screen
  • History of allergy or reaction to bee venom
  • Use of an agent or device within 30 days prior to dosing or current participation in an investigational study
  • history/presence of any gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease
  • Other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
  • Any clinically significant history/presence of poorly controlled neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, metabolic or other uncontrolled systemic disease
  • Blood donation (500 mL) within 7 days prior to study treatment
  • History of fever within 2 weeks of screening
  • Concomitant medical/psychiatric condition or social situation that would affect compliance or result in additional safety risk
  • Excessive exercise/physical activity within 3 days of screening or enrollment or planned during the study
  • History of thromboembolic disease, stroke within 6 months of baseline, and/or concurrent anticoagulant medication(s)

(Part B-Patients) - As for Part A with the following exceptions:

  • History of major surgery within 2 months of Screening
  • Forced expiratory volume at one second () at baseline \< 60%
  • AATD patients with liver elastography score > 11 at Screening
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Part A: 0.38 mg/kg

    Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part A: 1.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part A: 2.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part A: 3.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part A: 4.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part A: 5.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part A: 6.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part A: 7.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part A: 8.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Placebo comparator
    Part A: Placebo

    Single dose administration of 0.9% normal saline IV injection in healthy volunteers

    Other: Placebo · Drug: Diphenhydramine

  • Experimental
    Part B: 2.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part B: 4.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part B: 6.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Experimental
    Part B: 7.0 mg/kg

    Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD

    Drug: ARC-AAT Injection · Drug: Diphenhydramine

  • Placebo comparator
    Part B: Placebo

    Single dose administration of 0.9% normal saline IV injection in participants with AATD

    Other: Placebo · Drug: Diphenhydramine

Interventions

  • DrugARC-AAT Injection

    RNA interference-based, liver-targeted therapeutic

    Also known as: ARC-AAT

  • OtherPlacebo

    0.9 % normal saline

  • Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Discontinuations Due to TEAEs

    An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. SAEs are defined as is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.

    Time frame: From the first dose of study treatment through Day 29 ± 1 day

  2. Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Laboratory Values

    Laboratory values collected include: hematology (haemoglobin, lymphocytes, neutrophils, platelets, white cell count, monocytes); biochemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, creatine kinase, creatinine, gamma-glutamyltransferase, fasting glucose, troponin I); coagulation parameters (fibrinogen, international normalized ratio); and C-reactive protein.

    Time frame: Day 1 through Day 29 ± 1 day

  3. Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Vital Signs, Electrocardiograms (ECGs), Pulmonary Function, Physical Findings, and Other Observations

    Values collected include: vital signs (clinically concerning or symptomatic treatment emergent changes in heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, or temperature); ECGs (clinically significant changes from baseline were observed for ventricular rate, RR interval, QRS duration, QT interval or QT interval corrected for heart rate using Fridericia's formula \[QTcF\]; treatment emergent clinically significant changes in ST segments, P wave or T wave morphology; cardiac telemetry monitoring); clinically significant abnormal physical examination findings; treatment emergent sensitivity to bee venom; pulmonary function (clinically significant worsening in spirometry parameters and carbon monoxide diffusing capacity of the lung for carbon monoxide \[DLCO\]).

    Time frame: Day 1 through Day 29 ± 1 day

  4. Pharmacokinetics of ARC-AAT: Maximum Observed Plasma Concentration (Cmax) for the Analytes AD00370 and ARC-Melittin-Like Peptide (MLP; Part A)

    Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose

  5. Pharmacokinetics of ARC-AAT: Time to Maximum Observed Concentration (Tmax) for the Analytes AD00370 and ARC-MLP (Part A)

    Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose

  6. Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time 24 Hours (AUC0-24) for the Analytes AD00370 and ARC-MLP (Part A)

    Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose

  7. Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From From Zero to Infinity (AUCinf) for the Analytes AD00370 and ARC-MLP (Part A)

    Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose

  8. Pharmacokinetics of ARC-AAT: Terminal Elimination Rate Constant Obtained From the Slope of the Line (Kel) for the Analytes AD00370 and ARC-MLP (Part A)

    Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose

  9. Pharmacokinetics of ARC-AAT: Half-Life (t1/2) for the Analytes AD00370 and ARC-MLP (Part A)

    Time frame: Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose

  10. Percentage Reduction From Baseline of AAT Up to Day 29

    Clinical assay for total serum AAT level was used for Part A. A quantitative measurement of AAT was used for Part B. A negative percent reduction indicates a percentage increase. Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.

    Time frame: Baseline, Days 3, 8, 15, 22 and 29

Secondary outcomes

  1. Number of Participants With AAT Reduction > 30% From Baseline (First Occurrence)

    Data presents the study visit day upon which a participant had the first occurrence of AAT reduction of \> 30% from Baseline, and the number of participants who had a \> 30% reduction at any visit (overall). Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.

    Time frame: Baseline, Days 3, 8, 15, 22 and 29

  2. Maximum Percentage Reduction in Mean AAT (Nadir of Mean AAT)

    Time frame: Study Day for Nadir of Mean AAT: Day 8 (for Part B 2 mg/kg arm), Day 15 (for Part A 0.38 mg/kg, 2 mg/kg, 4 mg/ kg, Placebo arms; Part B 4 mg/kg, Placebo arms), Day 22 (Part A 3 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg arms), Day 29 (1 mg/kg, 8 mg/kg arms)

  3. Number of Participants With a Return From Nadir AAT Blood Levels to Above Normal or Within 15% of Baseline in > 100 Days

    Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.

    Time frame: Baseline, up to Day 29, and through 100 days of follow-up

  4. Mean Percentage Change in Circulating Blood Levels of Cytokines 2 Hours Post-Dose

    Time frame: Pre-dose, 2 hours post-dose

  5. Mean Percentage Change in Circulating Blood Levels of Complement Factors 2 Hours Post-Dose

    Time frame: Pre-dose, 2 hours post-dose

07

Results

Posted Aug 3, 2018

Participant flow

Participant flow — Overall Study
MilestonePart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
Started44444444418434
Completed44444443418434
Not completed0000000100000
Withdrew: Lost to follow-up0000000100000

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Discontinuations Due to TEAEs

An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. SAEs are defined as is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.

Time frame:
From the first dose of study treatment through Day 29 ± 1 day
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Discontinuations Due to TEAEs
participantsPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
TEAEs2221333139324
Study Drug Related TEAEs1121120031100
Mild or Moderate TEAEs2221333138324
Severe TEAEs0000000001000
Study Drug Related Moderate TEAEs1011000030000
Study Drug Related Severe TEAEs0000000000000
SAEs0000000001000
Discontinuations Due to TEAEs0000000000000
PrimaryNumber of Participants With Clinically Significant Treatment-Emergent Abnormalities in Laboratory Values

Laboratory values collected include: hematology (haemoglobin, lymphocytes, neutrophils, platelets, white cell count, monocytes); biochemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, creatine kinase, creatinine, gamma-glutamyltransferase, fasting glucose, troponin I); coagulation parameters (fibrinogen, international normalized ratio); and C-reactive protein.

Time frame:
Day 1 through Day 29 ± 1 day
Reported as:
Number · participants
Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Laboratory Values
participantsPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
Troponin I1000000000000
Neutrophils0000100000100
Creatine Kinase0000100000000
White Cell Count0000000000100
Monocytes0000000000100
Red Cell Distribution Width0000000000100
PrimaryNumber of Participants With Clinically Significant Treatment-Emergent Abnormalities in Vital Signs, Electrocardiograms (ECGs), Pulmonary Function, Physical Findings, and Other Observations

Values collected include: vital signs (clinically concerning or symptomatic treatment emergent changes in heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, or temperature); ECGs (clinically significant changes from baseline were observed for ventricular rate, RR interval, QRS duration, QT interval or QT interval corrected for heart rate using Fridericia's formula \[QTcF\]; treatment emergent clinically significant changes in ST segments, P wave or T wave morphology; cardiac telemetry monitoring); clinically significant abnormal physical examination findings; treatment emergent sensitivity to bee venom; pulmonary function (clinically significant worsening in spirometry parameters and carbon monoxide diffusing capacity of the lung for carbon monoxide \[DLCO\]).

Time frame:
Day 1 through Day 29 ± 1 day
Reported as:
Number · participants
Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Vital Signs, Electrocardiograms (ECGs), Pulmonary Function, Physical Findings, and Other Observations
participantsPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
Vital Signs0000000000000
ECGs0010000000000
Physical Examination Findings0000000001010
Bee Venom Sensitivity0000000000000
Pulmonary Function0000000001000
PrimaryPharmacokinetics of ARC-AAT: Maximum Observed Plasma Concentration (Cmax) for the Analytes AD00370 and ARC-Melittin-Like Peptide (MLP; Part A)
Time frame:
Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Reported as:
Mean · ng/mL
Pharmacokinetics of ARC-AAT: Maximum Observed Plasma Concentration (Cmax) for the Analytes AD00370 and ARC-Melittin-Like Peptide (MLP; Part A)
ng/mLPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kg
Analyte AD003704430 ± 117515500 ± 281132400 ± 700550650 ± 746175625 ± 815293275 ± 6133115750 ± 11871130250 ± 14127167000 ± 7810
Analyte ARC-MLP2760 ± 5089350 ± 236820700 ± 333427050 ± 539043425 ± 387248975 ± 559070050 ± 694662525 ± 402984733 ± 2875
Statistical analysis
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Alpha estimate: 9.557Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Beta estimate: 1.173 · 95% CI 1.128 to 1.218Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Alpha estimate: 9.824Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Beta estimate: 1.103 · 95% CI 1.054 to 1.153Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
PrimaryPharmacokinetics of ARC-AAT: Time to Maximum Observed Concentration (Tmax) for the Analytes AD00370 and ARC-MLP (Part A)
Time frame:
Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Reported as:
Median · hour
Pharmacokinetics of ARC-AAT: Time to Maximum Observed Concentration (Tmax) for the Analytes AD00370 and ARC-MLP (Part A)
hourPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kg
Analyte AD003700.083 (0.083 to 0.25)0.083 (0.083 to 0.083)0.083 (0.083 to 0.083)0.083 (0.083 to 0.50)0.083 (0.083 to 0.083)0.083 (0.083 to 0.50)0.083 (0.083 to 0.50)0.083 (0.083 to 0.50)0.50 (0.083 to 0.50)
Analyte ARC-MLP0.083 (0.083 to 0.25)0.083 (0.083 to 0.083)0.083 (0.083 to 0.083)0.083 (0.083 to 0.083)0.083 (0.083 to 0.50)0.083 (0.083 to 0.50)0.083 (0.083 to 1.00)0.50 (0.083 to 1.00)0.50 (0.50 to 0.50)
PrimaryPharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time 24 Hours (AUC0-24) for the Analytes AD00370 and ARC-MLP (Part A)
Time frame:
Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Reported as:
Mean · hr*ng/mL
Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time 24 Hours (AUC0-24) for the Analytes AD00370 and ARC-MLP (Part A)
hr*ng/mLPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kg
Analyte AD0037026905 ± 1079385138 ± 12234162198 ± 56129282710 ± 61810438532 ± 38111541628 ± 49787708648 ± 212442763392 ± 96095908117 ± 144892
Analyte ARC-MLP28734 ± 675782627 ± 32332213250 ± 67886291876 ± 58240458790 ± 48790459939 ± 81820699833 ± 85172716938 ± 467831011569 ± 101693
Statistical analysis
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Alpha estimate: 11.274Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Beta estimate: 1.181 · 95% CI 1.112 to 1.249Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Alpha estimate: 12.133Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Beta estimate: 1.147 · 95% CI 1.080 to 1.215Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
PrimaryPharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From From Zero to Infinity (AUCinf) for the Analytes AD00370 and ARC-MLP (Part A)
Time frame:
Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Reported as:
Mean · hr*ng/mL
Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From From Zero to Infinity (AUCinf) for the Analytes AD00370 and ARC-MLP (Part A)
hr*ng/mLPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kg
Analyte AD0037027388 ± 1118385906 ± 12529164856 ± 58070285487 ± 62310441239 ± 39032547045 ± 52126719843 ± 226599771924 ± 100469916343 ± 147924
Analyte ARC-MLP34718 ± 8345103116 ± 48837277684 ± 119873380506 ± 89117559372 ± 82769569056 ± 129569872798 ± 136277952668 ± 993241251318 ± 138571
Statistical analysis
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Alpha estimate: 11.286Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Beta estimate: 1.179 · 95% CI 1.110 to 1.249Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Alpha estimate: 12.347Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
  • Part A: 0.38 mg/kg vs Part A: 1.0 mg/kg vs Part A: 2.0 mg/kg vs Part A: 3.0 mg/kg vs Part A: 4.0 mg/kg vs Part A: 5.0 mg/kg vs Part A: 6.0 mg/kg vs Part A: 7.0 mg/kg vs Part A: 8.0 mg/kg · Beta estimate: 1.163 · 95% CI 1.081 to 1.245Estimation of model: Parameter = alpha \* Dose\^beta. Determined from linear regression model: Log(Parameter) = log(Dose)
PrimaryPharmacokinetics of ARC-AAT: Terminal Elimination Rate Constant Obtained From the Slope of the Line (Kel) for the Analytes AD00370 and ARC-MLP (Part A)
Time frame:
Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Reported as:
Mean · 1/hour
Pharmacokinetics of ARC-AAT: Terminal Elimination Rate Constant Obtained From the Slope of the Line (Kel) for the Analytes AD00370 and ARC-MLP (Part A)
1/hourPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kg
Analyte AD003700.186 ± 0.0500.177 ± 0.0040.170 ± 0.0130.174 ± 0.0040.185 ± 0.0110.183 ± 0.0060.185 ± 0.0230.178 ± 0.0100.181 ± 0.009
Analyte ARC-MLP0.0786 ± 0.01410.0879 ± 0.02970.0778 ± 0.02650.0762 ± 0.02180.0846 ± 0.01580.0815 ± 0.02310.0768 ± 0.01040.0622 ± 0.00770.0730 ± 0.0046
PrimaryPharmacokinetics of ARC-AAT: Half-Life (t1/2) for the Analytes AD00370 and ARC-MLP (Part A)
Time frame:
Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose
Reported as:
Mean · hours
Pharmacokinetics of ARC-AAT: Half-Life (t1/2) for the Analytes AD00370 and ARC-MLP (Part A)
hoursPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kg
Analyte AD003703.90 ± 0.843.91 ± 0.094.09 ± 0.313.99 ± 0.093.75 ± 0.223.78 ± 0.123.80 ± 0.533.90 ± 0.233.83 ± 0.19
Analyte ARC-MLP9.02 ± 1.508.60 ± 2.889.77 ± 3.399.83 ± 3.468.43 ± 1.688.93 ± 1.989.17 ± 1.4011.3 ± 1.59.52 ± 0.61
PrimaryPercentage Reduction From Baseline of AAT Up to Day 29

Clinical assay for total serum AAT level was used for Part A. A quantitative measurement of AAT was used for Part B. A negative percent reduction indicates a percentage increase. Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.

Time frame:
Baseline, Days 3, 8, 15, 22 and 29
Reported as:
Mean · percentage reduction
Percentage Reduction From Baseline of AAT Up to Day 29
percentage reductionPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
Day 3-4.70 ± 8.45-7.00 ± 3.19-1.94 ± 4.4913.76 ± 4.7420.76 ± 5.8621.65 ± 5.2822.20 ± 8.8020.35 ± 11.8330.07 ± 6.37-4.65 ± 11.1311.5 ± 11.543.8 ± 5.6-13.0 ± 31.9
Day 80.93 ± 2.8610.90 ± 8.3013.40 ± 11.6833.20 ± 14.3346.92 ± 6.1658.52 ± 6.1558.44 ± 7.5050.95 ± 6.8258.66 ± 2.99-0.26 ± 10.8043.1 ± 26.754.4 ± 22.27.0 ± 36.9
Day 155.00 ± 2.623.89 ± 2.7826.72 ± 14.3133.65 ± 14.6661.53 ± 11.7574.20 ± 7.0375.75 ± 5.9573.57 ± 2.7679.18 ± 4.030.78 ± 11.9137.5 ± 20.477.7 ± 1.57.2 ± 19.8
Day 221.42 ± 4.016.81 ± 8.8115.59 ± 9.2135.50 ± 15.2458.64 ± 13.5577.18 ± 9.9483.12 ± 3.6781.14 ± 1.1787.47 ± 2.090.50 ± 13.4825.1 ± 17.259.5 ± 13.41.7 ± 20.8
Day 290.19 ± 10.3725.87 ± 6.5813.93 ± 17.1627.40 ± 10.6550.02 ± 20.4673.15 ± 14.4682.99 ± 4.1978.20 ± 7.8387.93 ± 1.75-1.56 ± 8.6621.0 ± 24.465.2 ± 8.7-7.2 ± 30.3
SecondaryNumber of Participants With AAT Reduction > 30% From Baseline (First Occurrence)

Data presents the study visit day upon which a participant had the first occurrence of AAT reduction of \> 30% from Baseline, and the number of participants who had a \> 30% reduction at any visit (overall). Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.

Time frame:
Baseline, Days 3, 8, 15, 22 and 29
Reported as:
Number · participants
Number of Participants With AAT Reduction > 30% From Baseline (First Occurrence)
participantsPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
Overall0223444430231
Day 30000001120030
Day 80001443210201
Day 150022000000000
Day 220000000000000
Day 290200000100000
SecondaryMaximum Percentage Reduction in Mean AAT (Nadir of Mean AAT)
Time frame:
Study Day for Nadir of Mean AAT: Day 8 (for Part B 2 mg/kg arm), Day 15 (for Part A 0.38 mg/kg, 2 mg/kg, 4 mg/ kg, Placebo arms; Part B 4 mg/kg, Placebo arms), Day 22 (Part A 3 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg arms), Day 29 (1 mg/kg, 8 mg/kg arms)
Reported as:
Number · percentage reduction
Maximum Percentage Reduction in Mean AAT (Nadir of Mean AAT)
percentage reductionPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
Maximum Percentage Reduction in Mean AAT (Nadir of Mean AAT)5.025.926.735.561.577.283.181.187.90.7843.177.77.2
SecondaryNumber of Participants With a Return From Nadir AAT Blood Levels to Above Normal or Within 15% of Baseline in > 100 Days

Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.

Time frame:
Baseline, up to Day 29, and through 100 days of follow-up
Reported as:
Number · participants
Number of Participants With a Return From Nadir AAT Blood Levels to Above Normal or Within 15% of Baseline in > 100 Days
participantsPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
Number of Participants With a Return From Nadir AAT Blood Levels to Above Normal or Within 15% of Baseline in > 100 Days44444444418434
SecondaryMean Percentage Change in Circulating Blood Levels of Cytokines 2 Hours Post-Dose
Time frame:
Pre-dose, 2 hours post-dose
Reported as:
Mean · percentage change
Mean Percentage Change in Circulating Blood Levels of Cytokines 2 Hours Post-Dose
percentage changePart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
Serum interleukin-1 beta0 ± 00 ± 00 ± 00 ± 00 ± 00 ± 00 ± 0-9 ± 179 ± 180 ± 0-2 ± 10114 ± NA0 ± 0
Serum interleukin-65 ± 879 ± 14195 ± 11350 ± 64277 ± 308100 ± 191146 ± 261258 ± 285364 ± 255-1 ± 760 ± 52130 ± NA56 ± 91
Serum interleukin-832 ± 70280 ± 328336 ± 297103 ± 1011712 ± 981564 ± 576252 ± 363695 ± 6352015 ± 1569-6 ± 17197 ± 31946 ± NA-44 ± 13
Serum interleukin-10-5 ± 1972 ± 13451 ± 5242 ± 4527 ± 5419 ± 28116 ± 160377 ± 498638 ± 536-2 ± 70 ± 00 ± NA-5 ± 8
Serum interleukin-12p402 ± 372 ± 55 ± 86 ± 90 ± 00 ± 0152 ± 217-9 ± 1929 ± 38-3 ± 10-4 ± 1379 ± NA0 ± 0
Serum interleukin-12p700 ± 00 ± 00 ± 00 ± 054 ± 1080 ± 00 ± 0166 ± 38982 ± 130-1 ± 4-3 ± 548 ± NA23 ± 40
Serum monocyte chemoattractant protein-1123 ± 171442 ± 133505 ± 254632 ± 2811176 ± 4271297 ± 747543 ± 497906 ± 7202014 ± 4271 ± 13262 ± 26244 ± NA-27 ± 14
Serum macrophage inflammatory protein-1 alpha147 ± 126294 ± 275386 ± 556264 ± 4381674 ± 10221096 ± 578406 ± 4161003 ± 814854 ± 53815 ± 69246 ± 3040 ± NA0 ± 0
Serum tumor necrosis factor alpha66 ± 69207 ± 90286 ± 90187 ± 156818 ± 344476 ± 137301 ± 237761 ± 492742 ± 2733 ± 27107 ± 15255 ± NA-29 ± 11
Serum interferon alpha 20 ± 00 ± 00 ± 00 ± 00 ± 04 ± 773 ± 147172 ± 366515 ± 5295 ± 20-3 ± 7700 ± NA69 ± 119
SecondaryMean Percentage Change in Circulating Blood Levels of Complement Factors 2 Hours Post-Dose
Time frame:
Pre-dose, 2 hours post-dose
Reported as:
Mean · percentage change
Mean Percentage Change in Circulating Blood Levels of Complement Factors 2 Hours Post-Dose
percentage changePart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
Plasma Bb18 ± 1656 ± 2576 ± 37133 ± 29181 ± 185137 ± 8570 ± 63147 ± 73309 ± 174-7 ± 956 ± 6159 ± NA-14 ± 7
Serum C3a-12 ± 630 ± 42-22 ± 24-0 ± 871 ± 156-5 ± 1814 ± 5640 ± 5034 ± 30-11 ± 23-18 ± 23219 ± NA16 ± 40
Serum C4a-5 ± 737 ± 70-11 ± 102 ± 816 ± 13-8 ± 2778 ± 10760 ± 53-1 ± 15-19 ± 35-35 ± 21160 ± NA-15 ± 42
Serum C5a2 ± 72 ± 7-16 ± 5-2 ± 25-14 ± 72 ± 150 ± 86 ± 66 ± 12-2 ± 18-4 ± 1622 ± NA-4 ± 10
Serum CH50-5 ± 8-14 ± 11-14 ± 7-8 ± 8-16 ± 4-17 ± 8-10 ± 4-13 ± 13-19 ± 10-3 ± 9-3 ± 3-18 ± NA-0 ± 13

Adverse events

Collected over Day -1 through Day 29 ± 1 day. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: 0.38 mg/kg0/4 (0%)0/4 (0%)2/4 (50%)
Part A: 1.0 mg/kg0/4 (0%)0/4 (0%)2/4 (50%)
Part A: 2.0 mg/kg0/4 (0%)0/4 (0%)2/4 (50%)
Part A: 3.0 mg/kg0/4 (0%)0/4 (0%)1/4 (25%)
Part A: 4.0 mg/kg0/4 (0%)0/4 (0%)3/4 (75%)
Part A: 5.0 mg/kg0/4 (0%)0/4 (0%)3/4 (75%)
Part A: 6.0 mg/kg0/4 (0%)0/4 (0%)3/4 (75%)
Part A: 7.0 mg/kg0/4 (0%)0/4 (0%)1/4 (25%)
Part A: 8.0 mg/kg0/4 (0%)0/4 (0%)3/4 (75%)
Part A: Placebo0/18 (0%)1/18 (5.6%)9/18 (50%)
Part B: 2.0 mg/kg0/4 (0%)0/4 (0%)3/4 (75%)
Part B: 4.0 mg/kg0/3 (0%)0/3 (0%)2/3 (66.7%)
Part B: Placebo0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
RhabdomyolosisMusculoskeletal and connective tissue disorders0/40/40/40/40/40/40/40/40/41/180/40/30/4
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPart A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: Placebo
ChillsGeneral disorders0/40/40/40/40/40/40/40/43/40/180/40/30/4
Upper respiratory tract infectionInfections and infestations0/40/40/40/42/41/40/41/41/41/180/40/31/4
HeadacheNervous system disorders1/41/40/40/41/42/42/40/40/40/181/40/31/4
MigraineNervous system disorders0/40/40/40/40/41/40/40/40/40/180/41/30/4
CoughRespiratory, thoracic and mediastinal disorders0/40/40/40/40/40/40/40/40/40/180/41/31/4
DiarrhoeaGastrointestinal disorders0/40/40/41/40/40/40/40/40/40/180/41/30/4
Muscular weaknessMusculoskeletal and connective tissue disorders0/40/40/40/40/40/40/40/40/40/180/41/30/4
ConjunctivitisInfections and infestations0/40/40/40/40/40/40/40/41/40/180/40/30/4
NeutropeniaBlood and lymphatic system disorders0/40/40/40/41/40/40/40/40/40/180/40/30/4
ParaesthesiaNervous system disorders0/40/40/40/40/40/40/40/40/40/181/40/30/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: PlaceboTotal
Mean39.0 ± 9.825.0 ± 4.530.0 ± 7.829.5 ± 10.732.3 ± 5.623.8 ± 4.132.5 ± 15.326.0 ± 5.025.0 ± 1.825.4 ± 4.859.0 ± 1.864.3 ± 3.858.8 ± 9.033.4 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)Part A: 0.38 mg/kgPart A: 1.0 mg/kgPart A: 2.0 mg/kgPart A: 3.0 mg/kgPart A: 4.0 mg/kgPart A: 5.0 mg/kgPart A: 6.0 mg/kgPart A: 7.0 mg/kgPart A: 8.0 mg/kgPart A: PlaceboPart B: 2.0 mg/kgPart B: 4.0 mg/kgPart B: PlaceboTotal
Female1421143321231340
Male302330112612125
08

Study locations

4 sites
  • Research Site 1
    Melbourne, Victoria 3004, Australia
  • Research Site 2
    Homburg, Germany
  • Research Site 3
    Leiden, 2333ZA, Netherlands
  • Research Site 4
    Edgbaston, Birmingham B15 2WB, United Kingdom
09

References and documents

Publications

  • Turner AM, Stolk J, Bals R, Lickliter JD, Hamilton J, Christianson DR, Given BD, Burdon JG, Loomba R, Stoller JK, Teckman JH. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. J Hepatol. 2018 Aug;69(2):378-384. doi: 10.1016/j.jhep.2018.03.012. Epub 2018 Mar 21. PubMed 29572094 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2015
First posted
Feb 16, 2015
Start
Feb 2015
Primary completionActual
Nov 2016
CompletionActual
Nov 2016
Results first posted
Aug 3, 2018
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02363946
Responsible party
Sponsor
First posted
Feb 16, 2015
Start date
Feb 2015
Primary completion
Nov 2016
Completion
Nov 2016
Results posted
Aug 3, 2018
Last update
Jan 12, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion